Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.

Szczegóły
Abstrakt

Tytuł:: Evaluation of a Novel In-house HIV-1 Genotype Drug Resistance Assay using Clinical Samples in China.
Autorzy:: Gao P; Beijing Anapure Bioscitific Co. Ltd. Beijing, P.R. China.
Yu F; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Chaoyang District, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, P.R. China.
Yang X; Beijing Anapure Bioscitific Co. Ltd. Beijing, P.R. China.
Li D; Beijing Anapure Bioscitific Co. Ltd. Beijing, P.R. China.
Shi Y; Beijing Anapure Bioscitific Co. Ltd. Beijing, P.R. China.
Wang Y; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Chaoyang District, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, P.R. China.
Zhang F; Clinical and Research Center of Infectious Diseases, Beijing Ditan Hospital, Chaoyang District, China.; Clinical Center for HIV/AIDS, Capital Medical University, Beijing, P.R. China.
Źródło:: Current HIV research [Curr HIV Res] 2022; Vol. 20 (1), pp. 32-41.
Typ publikacji:: Journal Article; Research Support, Non-U.S. Gov't
Język:: English
Imprint Name(s):: Original Publication: [Hilversum, Netherlands] ; San Francisco, CA : Bentham Science Publishers, c2003-
MeSH Terms:: HIV Infections*
HIV Seropositivity*/drug therapy
HIV-1*/genetics
China/epidemiology ; Drug Resistance, Viral/genetics ; Genotype ; Humans ; Mutation ; Phylogeny ; Reverse Transcriptase Inhibitors/therapeutic use
References:: Sci Rep. 2015 Dec 15;5:18147. (PMID: 26667846)
AIDS Res Hum Retroviruses. 2020 Jul;36(7):616-624. (PMID: 32316742)
AIDS Res Hum Retroviruses. 2016 Sep;32(9):895-9. (PMID: 27169981)
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):244-248. (PMID: 32164137)
Infect Disord Drug Targets. 2018;18(1):15-22. (PMID: 28474549)
PLoS Med. 2007 Dec;4(12):e335. (PMID: 18052601)
J Biol Chem. 2010 Aug 27;285(35):26966-26975. (PMID: 20530477)
J Acquir Immune Defic Syndr. 2014 May 1;66(1):74-9. (PMID: 24413039)
J Infect. 2017 Aug;75(2):160-168. (PMID: 28551370)
Antivir Ther. 2008;13 Suppl 2:25-36. (PMID: 18575189)
PLoS One. 2012;7(10):e47289. (PMID: 23056619)
Emerg Microbes Infect. 2018 May 16;7(1):90. (PMID: 29769530)
J Acquir Immune Defic Syndr. 2012 Oct 1;61(2):153-7. (PMID: 22743599)
Sex Transm Infect. 2019 Sep;95(6):405-411. (PMID: 31266818)
BMC Infect Dis. 2014 May 05;14:237. (PMID: 24885612)
BMJ Glob Health. 2016 Sep 15;1(2):e000010. (PMID: 28588933)
Virol J. 2019 Apr 25;16(1):51. (PMID: 31023323)
Zhonghua Liu Xing Bing Xue Za Zhi. 2017 Oct 10;38(10):1367-1371. (PMID: 29060981)
Eur J Clin Microbiol Infect Dis. 2019 May;38(5):829-842. (PMID: 30798399)
AIDS Res Ther. 2016 Jan 19;13:3. (PMID: 26793263)
AIDS Res Hum Retroviruses. 2020 Feb;36(2):153-160. (PMID: 31547666)
BMC Res Notes. 2017 Apr 28;10(1):170. (PMID: 28454556)
Lancet HIV. 2017 Dec;4(12):e533-e534. (PMID: 28867268)
Int J Infect Dis. 2017 Feb;55:72-80. (PMID: 28082172)
AIDS. 2010 Jan 16;24(2):317-9. (PMID: 20010074)
J Infect Dis. 2013 Jun 15;207 Suppl 2:S45-8. (PMID: 23687288)
Curr Opin HIV AIDS. 2015 Jan;10(1):49-54. (PMID: 25389802)
Adv Exp Med Biol. 2018;1075:125-162. (PMID: 30030792)
Sci Rep. 2020 Mar 24;10(1):5295. (PMID: 32210333)
Scand J Infect Dis. 2012 Jan;44(1):65-9. (PMID: 21923627)
Clin Infect Dis. 2012 May;54 Suppl 4:S348-54. (PMID: 22544202)
J Acquir Immune Defic Syndr. 2015 Mar 1;68(3):289-97. (PMID: 25501612)
Nat Med. 2009 Aug;15(8):871-2. (PMID: 19648927)
AIDS Res Hum Retroviruses. 2018 Aug;34(8):714-718. (PMID: 29786452)
Nat Rev Microbiol. 2016 Jan;14(1):55-60. (PMID: 26616417)
AIDS Res Hum Retroviruses. 2020 Feb;36(2):143-152. (PMID: 31482724)
Expert Rev Anti Infect Ther. 2013 Nov;11(11):1159-78. (PMID: 24151833)
Epidemiol Infect. 2016 Jul;144(10):2144-53. (PMID: 26892485)
HIV Med. 2020 Dec;21(11):701-707. (PMID: 33369034)
AIDS Res Hum Retroviruses. 2019 Apr;35(4):419-423. (PMID: 30259751)
Medicine (Baltimore). 2020 Dec 24;99(52):e23638. (PMID: 33350740)
AIDS Res Hum Retroviruses. 2019 May;35(5):494-499. (PMID: 30681000)
J Pharmacol Sci. 2019 Apr;139(4):275-279. (PMID: 30928089)
Infect Dis Clin North Am. 2019 Sep;33(3):707-742. (PMID: 31255384)
Medicine (Baltimore). 2019 Oct;98(43):e17585. (PMID: 31651864)
J Virol Methods. 2013 Mar;188(1-2):97-103. (PMID: 23266258)
Clin Infect Dis. 2020 Jul 11;71(2):293-300. (PMID: 31612225)
Infect Genet Evol. 2019 Sep;73:109-112. (PMID: 31028881)
J Clin Virol. 2017 Jul;92:75-82. (PMID: 28599228)
Epidemiol Infect. 2019 Jan;147:e83. (PMID: 30869019)
Zhonghua Liu Xing Bing Xue Za Zhi. 2011 Sep;32(9):908-12. (PMID: 22340881)
Curr HIV/AIDS Rep. 2020 Feb;17(1):26-34. (PMID: 31939111)
PLoS One. 2016 Dec 20;11(12):e0166661. (PMID: 27997554)
Arch Virol. 2020 Jun;165(6):1453-1461. (PMID: 32279138)
Zhonghua Liu Xing Bing Xue Za Zhi. 2018 Jan 10;39(1):67-71. (PMID: 29374899)
Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Dec 10;40(12):1629-1633. (PMID: 32062928)
J Biol Chem. 2008 Aug 8;283(32):22222-32. (PMID: 18547911)
AIDS Res Hum Retroviruses. 2018 Apr;34(4):393-397. (PMID: 29258320)
Infect Dis Rep. 2013 Jun 06;5(Suppl 1):e4. (PMID: 24470968)
Sci Rep. 2018 Aug 16;8(1):12273. (PMID: 30115986)
Curr HIV Res. 2019;17(2):85-93. (PMID: 31269884)
Expert Rev Anti Infect Ther. 2014 Jul;12(7):783-91. (PMID: 24745361)
BMC Infect Dis. 2019 Apr 8;19(1):313. (PMID: 30961560)
J Virol. 2014 Feb;88(3):1536-47. (PMID: 24227862)
Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. (PMID: 20124001)
Acta Clin Belg. 2014 Oct;69(5):348-57. (PMID: 25103592)
AIDS Res Hum Retroviruses. 2019 Feb;35(2):155-163. (PMID: 30430838)
Curr Opin HIV AIDS. 2019 May;14(3):153-160. (PMID: 30882484)
HIV Med. 2017 Jan;18(1):21-32. (PMID: 27353061)
Curr Opin HIV AIDS. 2018 Sep;13(5):416-421. (PMID: 29878912)
BMC Res Notes. 2017 Nov 10;10(1):589. (PMID: 29126456)
Curr Opin Pharmacol. 2019 Oct;48:24-32. (PMID: 31029861)
Am J Clin Pathol. 2019 Oct 7;152(5):558-562. (PMID: 31365738)
PLoS One. 2014 Jun 30;9(6):e99693. (PMID: 24978029)
Open AIDS J. 2015 Feb 27;9:9-13. (PMID: 25767633)
BMC Infect Dis. 2013 Nov 04;13:517. (PMID: 24180455)
Contributed Indexing:: Keywords: HIV-1; anti-retroviral treatment; drug resistance mutation; genotype; non-Nucleoside reverse transcriptase inhibitors.; nucleoside reverse transcriptase inhibitors; protease inhibitor
Substance Nomenclature:: 0 (Reverse Transcriptase Inhibitors)
Entry Date(s):: Date Created: 20210913 Date Completed: 20220502 Latest Revision: 20220716
Update Code:: 20240105
PubMed Central ID:: PMC9127726
DOI:: 10.2174/1570162X19666210910144433
PMID:: 34515004
: Czasopismo naukowe

Background: HIV drug resistance poses a major challenge for anti-retroviral treatment (ART) and the prevention and control of HIV epidemic.
Objective: The study aims to establish a novel in-house assay with high efficiency, named AP inhouse method, that would be suitable for HIV-1 drug resistance detection in China.
Methods: An in-house HIV-1 genotyping method was used to sequence the partial pol gene from 60 clinical plasma samples; the results of our test were compared with a commercial ViroSeq HIV-1 genotyping system.
Results: Among sixty samples, 58(96.7%) were successfully amplified by AP in-house method, five of them harbored viral load below 1,000 copies/ml. The genotype distribution was 43.1% CRF07_ BC (25/58), 39.7% CRF01_AE (23/58), 6.9% CRF55_01B (4/58), 5.2% subtype B (3/58) and 5.2% CRF08_BC (3/58). Compared with that of the ViroSeq system, the consistent rate of these nucleotides and amino acids obtained by AP in-house method was up to 99.5 ± 0.4% and 99.5 ± 0.4%, respectively. A total of 290 HIV-1 drug resistance mutations were identified by two methods, including 126 nucleoside reverse transcriptase inhibitors (NRTIs), 145 non-nucleoside reverse transcriptase inhibitors (NNRTIs) and 19 protease inhibitors (PIs) resistance mutations. Out of them, 94.1% (273/290) were completely concordant between the AP in-house method and the ViroSeq system.
Conclusion: Overall, the evaluation of AP in-house method provided comparable results to those of the ViroSeq system on diversified HIV-1 subtypes in China.
(Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.)

Informacja